V Nelahozevsi na Mělnicku ve čtvrtek ráno vykolejil nákladní vlak. Kvůli problému byla přerušena doprava na frekventované železniční trati z Ústí nad Labem do Prahy. Jak se incident stal, zatím není jasné.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Ardagh Group S.A. - Fourth Quarter and Full Year 2020 Results
February 16, 2021 GMT
Ardagh Group logo 2019 (PRNewsfoto/Ardagh Group S.A.)
LUXEMBOURG, Feb. 16, 2021 /PRNewswire/ Ardagh Group S.A. (NYSE: ARD) today announced its results for the fourth quarter and year ended December 31, 2020. December 31,
Full Year
35
1.44
(27)
(0.11)
0.28
0.15
4.9x
4.5x
Paul Coulson, Chairman and Chief Executive, said: “The Group performed well in the quarter, with strong earnings growth in Metal Beverage Packaging and volume growth in Glass Packaging. The resilience of our businesses, the adaptability of our teams and the outlook for our sustainable products was underlined in 2020. We remain focused on growth and have increased our 2021-2024 Business Growth Investment program from $1.8 billion to $2.1 billion due to additional beverage can opportunities. These highly accretive investments
5%
Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing a loss of response requiring rescue treatment compared to those randomized to placebo. Both doses also met the key secondary endpoint of a larger percentage of patients maintaining an Investigator’s Global Assessment (IGA) response of clear or almost clear relative to placebo.